Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients
Study sponsor: Cerus Corporation
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-12-04Actual
Enrollment · participants581Actual
Source updated2026-09-22Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.